Drug intelligence / Profile preview

xibofen

Development stage: Preclinical
Lead developer: Boots
Modality: Small Molecules
Administration: Intravesical

Overview

Xibofen is a photosensitizer drug investigated for use in photodynamic therapy (PDT), specifically in combination with intravesical BCG perfusion immunotherapy for the prevention of recurrence of non-muscle invasive bladder cancer. Photodynamic therapy involves the administration of a photosensitizing agent, which is then activated by light of a specific wavelength. This activation leads to the generation of reactive oxygen species, which are toxic to cancerous and precancerous cells, causing their destruction. PDT can also stimulate an immune response against the treated cells.

Beyond the preview

Go deeper on xibofen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xibofen.

Explore the full profile